Method of treatment of diabetes and/or obesity with reduced nausea side effect
First Claim
1. A method of administering an insulinotropic peptide to a nausea-sensitive subject comprising administering to said nausea-sensitive subject the insulinotropic peptide conjugated to albumin, wherein the conjugated insulinotropic peptide reduces nausea compared to administration of the unconjugated insulinotropic peptide.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provides methods of selecting a subject for administration of a conjugated insulinotropic peptide. Exemplary disorders or conditions treatable with an insulinotropic peptide include obesity and type II diabetes.
181 Citations
43 Claims
- 1. A method of administering an insulinotropic peptide to a nausea-sensitive subject comprising administering to said nausea-sensitive subject the insulinotropic peptide conjugated to albumin, wherein the conjugated insulinotropic peptide reduces nausea compared to administration of the unconjugated insulinotropic peptide.
-
20. (canceled)
-
21. (canceled)
-
30. A method of selecting a subject for treatment with an insulinotropic peptide conjugated to albumin, comprising the step of identifying a nausea sensitive subject having a disease or disorder treatable with the insulinotropic peptide, wherein the subject is selected for treatment when the subject is prone to experiencing or is experiencing nausea.
-
32. A method of administering an insulinotropic peptide to a subject comprising (a) selecting a nausea sensitive subject having a disease or disorder treatable with the insulinotropic peptide;
- and (b) administering to the subject the insulinotropic peptide conjugated to albumin wherein the conjugated insulinotropic peptide reduces nausea compared to administering the unconjugated insulinotropic peptide.
-
33. A unit dose pharmaceutical comprising 1250 μ
- g of a conjugate according to the following;
- g of a conjugate according to the following;
-
34. A unit dose pharmaceutical comprising 2500 μ
- g of a conjugate according to the following;
- g of a conjugate according to the following;
-
35. A unit dose pharmaceutical comprising 3750 μ
- g of a conjugate according to the following;
- View Dependent Claims (37, 38, 39, 40, 41)
- g of a conjugate according to the following;
-
36. A method for the treatment of diabetes or obesity in a subject, comprising
a. selecting a nausea-sensitive subject in need of said treatment, and b. administering an insulinotropic peptide linked to albumin to the selected subject, wherein the administration of the insulinotropic peptide linked to albumin provides a reduced nausea side effect compared to the administration of the insulinotropic peptide alone.
Specification